opentargets/clinical_trial_reason_to_stop · Datasets at Hugging Face

text stringlengths 4 164	label_descriptions sequence	Another_Study bool 2 classes	Business_Administrative bool 2 classes	Covid19 bool 2 classes	Endpoint_Met bool 2 classes	Ethical_Reason bool 2 classes	Insufficient_Data bool 2 classes	Insufficient_Enrollment bool 2 classes	Interim_Analysis bool 2 classes	Invalid_Reason bool 2 classes	Logistics_Resources bool 2 classes	Negative bool 2 classes	No_Context bool 2 classes	Regulatory bool 2 classes	Safety_Sideeffects bool 2 classes	Study_Design bool 2 classes	Study_Staff_Moved bool 2 classes	Success bool 2 classes
All the patients were included	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Alternate study projected to assess imaging endpoints versus clinical endpoints.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Alternative trial planned	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Amendment requested for this study - waiting for Regulatory Approval of the Amendment	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Amgen decision following interim review of efficacy and safety data from the AMG 337 program.	[ "Interim_Analysis" ]	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false
Amgen determined no further need for this study.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
An alternative joint industry effort will provide information on combination versus singleÊ agent therapy for treatment of aspergillosis	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
An endpoint difference between 3 energies was not observed. Correlations between recovery and ATP were established, and will be used for a Whole Blood system."	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
An independent DMC determined continuation was unlikely to demonstrate a statistically significant advantage of ASP8825 over placebo on the primary endpoint	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
An interim analysis revealed a significantly higher persistence/recurrence of complications of portal hypertension in the 8 mm-stent group.	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
An interim analysis showed that nitric oxide patches are not enough effective	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
An interim data analysis found no significant difference between testing groups.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Analysis of data from 104RA202 failed to meet primary endpoint	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Analysis of data from 104RA203 failed to meet primary endpoint.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Ancillary data being reviewed to determine if this study will continue.	[ "Interim_Analysis" ]	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false
Angioscanners in excess of the SNA group because of use of thiopental	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Animal Safety Data	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Animal Toxicity Findings	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Another study enrolling the similar group of patient are ongoing	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Another study has been planned, so we did not initiate this one.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Another study was opened.	[ "Business_Administrative", "Another_Study" ]	true	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Another treatment found efficacious	[ "Business_Administrative", "Another_Study" ]	true	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Another trial in the department directly competes for the the same patient population	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Anticipated number of patients not achieved. All Patients recruited in the study completed all study visits.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Anticipation of inadequate recruitment according to current format.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Approval lapse	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
Arm A - reached goal; Arm B - poor accrual	[ "Insufficient_Enrollment", "Endpoint_Met" ]	false	false	false	true	false	false	true	false	false	false	false	false	false	false	false	false	false
As Continuing Review application to IRB was not submitted on time	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
As another Mps1 inhibitor was being developed in parallel, the strategic decision was to moveÊ forward with the development of the follow up compound only.	[ "Business_Administrative", "Logistics_Resources" ]	false	true	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
As no safety warnings were detected,Interim analysis from the first 40 patients reccomends to stop the trial for futility"	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
As recommended by the DSMB.	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
As the recruitment rate was very low, a futility study was conducted and it was decided toÊ discontinue inclusions	[ "Insufficient_Enrollment", "Negative" ]	false	false	false	false	false	false	true	false	false	false	true	false	false	false	false	false	false
Assessing resources needed to extend study.	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
AstraZeneca has discontinued the development of AZD0530. No new AstraZeneca-sponsored clinical studies will be initiated..	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
AstraZeneca withdrew support for the study.	[ "Business_Administrative", "Logistics_Resources" ]	false	true	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
At half the sample size, the results were negative with no benefit demonstrated with Ê adenosine.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
At interim analysis the study did not meet the response criteria to continue	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
At sponsor's discretion	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line therapy for of uncomplicated malaria."	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
At the first prespecified interim analysis	[ "Interim_Analysis" ]	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false
Attendance at study sites carries risk of COVID-19 infection. Non-attendance at planned study	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Authorization denied	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Autorities vorbidden this dispositif in other trial	[ "Study_Design", "Safety_Sideeffects", "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	true	true	false	false
Availability of Investigational agent	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Avastin approved for first-in-line treatment.	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Awaiting IMP license for new GMP suite.	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct thisÊ study.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
B2151007 was prematurely discontinued due to Pfizer's change in prioritization for theÊ portfolio and is not due to any safety concerns or regulatory interaction	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
BMS withdrew support and required this trial to stop enrolling; Phase II portion never began,Ê only a Phase I trial.	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
Based on Independent Data Monitoring Committee (IDMC) recommendation.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Based on a business decision unrelated to any safety concerns.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Based on a consistently low enrolment rate and procedural challenges that were unknown at study start. It was not based on safety or efficacy concerns.	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Based on an interim data review, the DSMB concluded that the vaccine cannot be shown in this trial to prevent HIV infection or affect the course of the disease."	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Based on analyses in Phase I, the study did not advance to Phase II.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Based on analysis of results and consideration of available treatments, the overall benefit toÊ risk profile of ocrelizumab was not favorable in RA.	[ "Business_Administrative", "Negative" ]	false	true	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Based on data collected, the combination appeared to be poorly tolearated."	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Based on futility analysis showing <30% chance of meeting primary endpoint.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Based on input from regulatory agencies, it is not necessary to conduct this study. An ongoing study was sufficient for regulatory purposes."	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Based on interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment was stopped due to lack of efficacy"	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Based on interim analysis at the end of Stage 1, and predefined stopping rules for futility,Ê further enrollment was stopped due to lack of efficacy	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Based on overall benefit-risk assessment.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Based on preliminary parent study results	[ "No_Context", "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false
Based on the data and observed benefit-risk profile, the trial's independent oversight committee recommended that enrollment not resume."	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly tolerated."	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Based on the outcome of the planned first interim analysis, it was decided not to continue the trial. No safety concerns were identified."	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Based on the results of the Phase 1 data, the company decided not to pursue the development ofÊ this drug at this time.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Based upon preliminary safety and efficacy results from a similar study.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Bayer Healthcare is no supplying the study drug	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Bayer terminated the program and sold the IP to Medronic	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Beacuse of unexpected administrative barriers, only 5 cases were enrolled in a year."	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Because of a strategic decision by Novartis	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line setting."	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Because of lack of funding and recruitment problems the study has been closed.	[ "Logistics_Resources", "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	true	false	false	false	false	false	false	false
Because of many competing trials using the same mechanism of action, but being further advancedÊ in development	[ "Business_Administrative", "Study_Design" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Because of negative results of the sister study NAK-06 and the low overall response rate atÊ week 24.	[ "Another_Study", "Negative" ]	true	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Because of slow recruitment; Despite the study was started long time ago (Oct 2004), we have not reached the projected number of patients (150 patients)"	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Because of the economic consequences of the COVID-19 pandemic 2020	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Because of the epidemic of COVID-19, the serum testing could not be continued	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Because of the low probability of achieving the primary endpoint.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Because of unexpectedly reduced disease prevalence in the study area, a pragmatic decision was taken to terminate recruitment in March 2003."	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Because of unsatisfactory results of previous trial which assessed the effect of different onset times of PDL on surgical scars.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Because of very slow rate of enrollement	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Because of withdrawal of Avandia sale due to its risks outweigh its benefits	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Because only a few patients follow the inclusion and exclusion criteria.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Because there was no longer an active laboratory component to this study.	[ "Logistics_Resources", "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	true	false
Because we did not find funds to do it	[ "Business_Administrative", "Invalid_Reason" ]	false	true	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Big difficulties to enroll patients	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Boston Scientific has decided to close the Study.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Both sponsor and UCSF decided this study was not clinical relevant at this time	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Budget issues	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Budgetary	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Budgetary restrictions	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Bupivacaine has recently been shown to inhibit osteoclast formation in vitro.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business Decision	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business Decision; No Safety Concerns	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business Decision; No Safety Or Efficacy Concerns.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business Objectives Changed	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business Objectives Have Changed	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Business Reasons	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false

All the patients were included

[ "Invalid_Reason" ]

false

true

false

Alternate study projected to assess imaging endpoints versus clinical endpoints.

[ "Another_Study" ]

true

false

Alternative trial planned

[ "Study_Design" ]

false

true

false

Amendment requested for this study - waiting for Regulatory Approval of the Amendment

[ "Study_Design" ]

false

true

false

Amgen decision following interim review of efficacy and safety data from the AMG 337 program.

[ "Interim_Analysis" ]

false

true

false

Amgen determined no further need for this study.

[ "Business_Administrative" ]

false

true

false

An alternative joint industry effort will provide information on combination versus singleÊ agent therapy for treatment of aspergillosis

[ "Another_Study" ]

true

false

An endpoint difference between 3 energies was not observed. Correlations between recovery and ATP were established, and will be used for a Whole Blood system."

[ "Negative" ]

false

true

false

An independent DMC determined continuation was unlikely to demonstrate a statistically significant advantage of ASP8825 over placebo on the primary endpoint

[ "Negative" ]

false

true

false

An interim analysis revealed a significantly higher persistence/recurrence of complications of portal hypertension in the 8 mm-stent group.

[ "Safety_Sideeffects" ]

false

true

false

An interim analysis showed that nitric oxide patches are not enough effective

[ "Negative" ]

false

true

false

An interim data analysis found no significant difference between testing groups.

[ "Negative" ]

false

true

false

Analysis of data from 104RA202 failed to meet primary endpoint

[ "Negative" ]

false

true

false

Analysis of data from 104RA203 failed to meet primary endpoint.

[ "Negative" ]

false

true

false

Ancillary data being reviewed to determine if this study will continue.

[ "Interim_Analysis" ]

false

true

false

Angioscanners in excess of the SNA group because of use of thiopental

[ "Logistics_Resources" ]

false

true

false

Animal Safety Data

[ "Another_Study" ]

true

false

Animal Toxicity Findings

[ "Safety_Sideeffects" ]

false

true

false

Another study enrolling the similar group of patient are ongoing

[ "Another_Study" ]

true

false

Another study has been planned, so we did not initiate this one.

[ "Another_Study" ]

true

false

Another study was opened.

[ "Business_Administrative", "Another_Study" ]

true

false

Another treatment found efficacious

[ "Business_Administrative", "Another_Study" ]

true

false

Another trial in the department directly competes for the the same patient population

[ "Another_Study" ]

true

false

Anticipated number of patients not achieved. All Patients recruited in the study completed all study visits.

[ "Insufficient_Enrollment" ]

false

true

false

Anticipation of inadequate recruitment according to current format.

[ "Insufficient_Enrollment" ]

false

true

false

Approval lapse

[ "Regulatory" ]

false

true

false

Arm A - reached goal; Arm B - poor accrual

[ "Insufficient_Enrollment", "Endpoint_Met" ]

false

true

false

true

false

As Continuing Review application to IRB was not submitted on time

[ "Business_Administrative" ]

false

true

false

As another Mps1 inhibitor was being developed in parallel, the strategic decision was to moveÊ forward with the development of the follow up compound only.

[ "Business_Administrative", "Logistics_Resources" ]

false

true

false

true

false

As no safety warnings were detected,Interim analysis from the first 40 patients reccomends to stop the trial for futility"

[ "Negative" ]

false

true

false

As recommended by the DSMB.

[ "Regulatory" ]

false

true

false

As the recruitment rate was very low, a futility study was conducted and it was decided toÊ discontinue inclusions

[ "Insufficient_Enrollment", "Negative" ]

false

true

false

true

false

Assessing resources needed to extend study.

[ "Logistics_Resources" ]

false

true

false

AstraZeneca has discontinued the development of AZD0530. No new AstraZeneca-sponsored clinical studies will be initiated..

[ "Business_Administrative" ]

false

true

false

AstraZeneca withdrew support for the study.

[ "Business_Administrative", "Logistics_Resources" ]

false

true

false

true

false

At half the sample size, the results were negative with no benefit demonstrated with Ê adenosine.

[ "Negative" ]

false

true

false

At interim analysis the study did not meet the response criteria to continue

[ "Negative" ]

false

true

false

At sponsor's discretion

[ "Business_Administrative" ]

false

true

false

At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line therapy for of uncomplicated malaria."

[ "Study_Design" ]

false

true

false

At the first prespecified interim analysis

[ "Interim_Analysis" ]

false

true

false

Attendance at study sites carries risk of COVID-19 infection. Non-attendance at planned study

[ "Covid19" ]

false

true

false

Authorization denied

[ "Invalid_Reason" ]

false

true

false

Autorities vorbidden this dispositif in other trial

[ "Study_Design", "Safety_Sideeffects", "Regulatory" ]

false

true

false

Availability of Investigational agent

[ "Logistics_Resources" ]

false

true

false

Avastin approved for first-in-line treatment.

[ "Study_Design" ]

false

true

false

Awaiting IMP license for new GMP suite.

[ "Regulatory" ]

false

true

false

Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct thisÊ study.

[ "Business_Administrative" ]

false

true

false

B2151007 was prematurely discontinued due to Pfizer's change in prioritization for theÊ portfolio and is not due to any safety concerns or regulatory interaction

[ "Business_Administrative" ]

false

true

false

BMS withdrew support and required this trial to stop enrolling; Phase II portion never began,Ê only a Phase I trial.

[ "Regulatory" ]

false

true

false

Based on Independent Data Monitoring Committee (IDMC) recommendation.

[ "Negative" ]

false

true

false

Based on a business decision unrelated to any safety concerns.

[ "Business_Administrative" ]

false

true

false

Based on a consistently low enrolment rate and procedural challenges that were unknown at study start. It was not based on safety or efficacy concerns.

[ "Logistics_Resources" ]

false

true

false

Based on an interim data review, the DSMB concluded that the vaccine cannot be shown in this trial to prevent HIV infection or affect the course of the disease."

[ "Negative" ]

false

true

false

Based on analyses in Phase I, the study did not advance to Phase II.

[ "Another_Study" ]

true

false

Based on analysis of results and consideration of available treatments, the overall benefit toÊ risk profile of ocrelizumab was not favorable in RA.

[ "Business_Administrative", "Negative" ]

false

true

false

true

false

Based on data collected, the combination appeared to be poorly tolearated."

[ "Safety_Sideeffects" ]

false

true

false

Based on futility analysis showing <30% chance of meeting primary endpoint.

[ "Negative" ]

false

true

false

Based on input from regulatory agencies, it is not necessary to conduct this study. An ongoing study was sufficient for regulatory purposes."

[ "Another_Study" ]

true

false

Based on interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment was stopped due to lack of efficacy"

[ "Negative" ]

false

true

false

Based on interim analysis at the end of Stage 1, and predefined stopping rules for futility,Ê further enrollment was stopped due to lack of efficacy

[ "Negative" ]

false

true

false

Based on overall benefit-risk assessment.

[ "Business_Administrative" ]

false

true

false

Based on preliminary parent study results

[ "No_Context", "Another_Study" ]

true

false

true

false

Based on the data and observed benefit-risk profile, the trial's independent oversight committee recommended that enrollment not resume."

[ "Negative" ]

false

true

false

Based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly tolerated."

[ "Safety_Sideeffects" ]

false

true

false

Based on the outcome of the planned first interim analysis, it was decided not to continue the trial. No safety concerns were identified."

[ "Negative" ]

false

true

false

Based on the results of the Phase 1 data, the company decided not to pursue the development ofÊ this drug at this time.

[ "Negative" ]

false

true

false

Based upon preliminary safety and efficacy results from a similar study.

[ "Another_Study" ]

true

false

Bayer Healthcare is no supplying the study drug

[ "Logistics_Resources" ]

false

true

false

Bayer terminated the program and sold the IP to Medronic

[ "Business_Administrative" ]

false

true

false

Beacuse of unexpected administrative barriers, only 5 cases were enrolled in a year."

[ "Business_Administrative" ]

false

true

false

Because of a strategic decision by Novartis

[ "Business_Administrative" ]

false

true

false

Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line setting."

[ "Study_Design" ]

false

true

false

Because of lack of funding and recruitment problems the study has been closed.

[ "Logistics_Resources", "Insufficient_Enrollment" ]

false

true

false

true

false

Because of many competing trials using the same mechanism of action, but being further advancedÊ in development

[ "Business_Administrative", "Study_Design" ]

false

true

false

true

false

Because of negative results of the sister study NAK-06 and the low overall response rate atÊ week 24.

[ "Another_Study", "Negative" ]

true

false

true

false

Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim

[ "Study_Design" ]

false

true

false

Because of slow recruitment; Despite the study was started long time ago (Oct 2004), we have not reached the projected number of patients (150 patients)"

[ "Insufficient_Enrollment" ]

false

true

false

Because of the economic consequences of the COVID-19 pandemic 2020

[ "Covid19" ]

false

true

false

Because of the epidemic of COVID-19, the serum testing could not be continued

[ "Covid19" ]

false

true

false

Because of the low probability of achieving the primary endpoint.

[ "Negative" ]

false

true

false

Because of unexpectedly reduced disease prevalence in the study area, a pragmatic decision was taken to terminate recruitment in March 2003."

[ "Insufficient_Enrollment" ]

false

true

false

Because of unsatisfactory results of previous trial which assessed the effect of different onset times of PDL on surgical scars.

[ "Another_Study" ]

true

false

Because of very slow rate of enrollement

[ "Insufficient_Enrollment" ]

false

true

false

Because of withdrawal of Avandia sale due to its risks outweigh its benefits

[ "Safety_Sideeffects" ]

false

true

false

Because only a few patients follow the inclusion and exclusion criteria.

[ "Insufficient_Enrollment" ]

false

true

false

Because there was no longer an active laboratory component to this study.

[ "Logistics_Resources", "Study_Staff_Moved" ]

false

true

false

true

false

Because we did not find funds to do it

[ "Business_Administrative", "Invalid_Reason" ]

false

true

false

true

false

Big difficulties to enroll patients

[ "Insufficient_Enrollment" ]

false

true

false

Boston Scientific has decided to close the Study.

[ "Business_Administrative" ]

false

true

false

Both sponsor and UCSF decided this study was not clinical relevant at this time

[ "Business_Administrative" ]

false

true

false

Budget issues

[ "Business_Administrative" ]

false

true

false

Budgetary

[ "Business_Administrative" ]

false

true

false

Budgetary restrictions

[ "Business_Administrative" ]

false

true

false

Bupivacaine has recently been shown to inhibit osteoclast formation in vitro.

[ "Another_Study" ]

true

false

Business Decision

[ "Business_Administrative" ]

false

true

false

Business Decision; No Safety Concerns

[ "Business_Administrative" ]

false

true

false

Business Decision; No Safety Or Efficacy Concerns.

[ "Business_Administrative" ]

false

true

false

Business Objectives Changed

[ "Business_Administrative" ]

false

true

false

Business Objectives Have Changed

[ "Business_Administrative" ]

false

true

false

Business Reasons

[ "Business_Administrative" ]

false

true

false